Join us for 2 days of lively discussion on FCA enforcement including the ramifications of two Supreme Court decisions and the evolution of the pandemic, cybersecurity, and telehealth fraud.
This conference aims to provide the clarity you need in this evolving environment. Join us live in NYC to hear directly from government enforcers, cross-industry compliance and investigations counsel, and top attorneys from both the defense and relators’ bar on how to prepare for the next wave of FCA enforcement and avoid becoming a target of government action.
Advisory Board
Get exclusive insights from our esteemed False Claims and Qui Tam Enforcement advisory board, whose expertise and input are instrumental in shaping each year’s comprehensive program.
Board members include: Samford University | BAE Systems, Inc. | Lockheed Martin Corporation | Northwell Health | Pfizer | Fluor Mission Solutions | U.S. Bancorp | GE Aerospace | Bristol-Myers Squibb Company
145+
Attendees
14
Key Sessions
43
Speakers
2
Days of Networking
Why Attend
Fiscal Year 2023 marked the fifteenth straight year of recoveries exceeding $2 billion, hitting a record $2.68. Over $1.8 billion of these recoveries come from the healthcare industry alone. With an emphasis on data from enforcers and relators, and incentive programs encouraging whistleblowers, the FCA remains a steadfast tool that promises to only get stronger.
DOJ has continued to utilize data across the enforcement landscape, diving deeper into pandemic-related fraud and Medicare advantage matters, identifying outliers to indicate likely fraud. Additionally, whistleblowers and relators filed 712 qui tam cases in 2023, with settlements and judgements exceeding $2.3 billion. With the introduction of the DOJ’s new Corporate Whistleblower Awards Pilot Program, the intersection of the Anti-Kickback Statute and the FCA, and rigorous investigations into the minutiae of fraud, enforcement efforts have never been more powerful.
Considering judicial questions surrounding knowledge standards for liability, cybersecurity adequacy, and the constitutional validity of the qui tam provision, the future of the False Claims Act landscape remains uncertain.
Who Attends
- General Counsel
- Chief Legal Counsel
- Assistant General Counsel
- In-House Counsel
- Litigators
Outside Counsel specializing in:
- False Claims Act
- Fraud
- Corporate Compliance
- White Collar Crime
- Government Contracts
- Healthcare
- Life Sciences
- Financial Services
Past Attending Organizations
- Abbott Laboratories
- BAE Systems
- GE Aerospace
- Gilead Sciences
- Lockheed Martin
- Medtonic
- Merck
- Northwell Health
- OptumRx
- Pfizer
CLE Accreditation
Accreditation will be sought in those jurisdictions requested by the registrants which have continuing education requirements. This course is identified as nontransitional for the purposes of CLE accreditation.
Learn more“Great mix of panelists and topics, very well run, timely and fresh, great mix of constituents (defense counsel, Relator’s bar, industry, and government).”
“[This conference] provides valuable insight into how the various stakeholders analyze FCA issues – industry, prosecutors, and Relator counsel.”
“The panels were excellent with great content. I thought the topics were very relevant. Excellent speakers. I liked the venue. Catering was also good.”
Sponsor Opportunities
With conferences in the United States, Europe, Asia Pacific, and Latin America, the C5 Group of Companies: American Conference Institute, the Canadian Institute, and C5 Group, provides a diverse portfolio of conferences, events and roundtables devoted to providing business intelligence to senior decision makers responding to challenges around the world.
For more information please contact:
Aaron Goldstein
Senior Business Development Manager
Email: [email protected]
